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Abstract
Objectives. To evaluate the risk of serious infections (SIs) in patients with RA treated with anti-TNF
therapy with emphasis on the risk across different ages.
Methods. Using data from the British Society for Rheumatology Biologics Register, a prospective obser-
vational study, we compared the risk of SI between 11798 anti-TNF-treated patients and 3598
non-biologic DMARD (nbDMARD)-treated patients.
Results. A total of 1808 patients had at least one SI (anti-TNF: 1512; nbDMARD: 296). Incidence rates
were: anti-TNF 42/1000 patient-years of follow-up (95% CI 40, 44) and nbDMARD 32/1000 patient-years
of follow-up (95% CI 28, 36). The adjusted hazard ratio (adjHR) for SI in the anti-TNF cohort was 1.2 (95%
CI 1.1, 1.5). The risk did not differ significantly between the three agents adalimumab, etanercept and
infliximab. The risk was highest during the first 6 months of therapy [adjHR 1.8 (95% CI 1.3, 2.6)]. Although
increasing age was an independent risk factor for SI in both cohorts, there was no difference in relative
risk of infection in patients on anti-TNF therapy in the older population. There was no difference in hospital
stay for SI between cohorts. Mortality within 30 days of SI was 50% lower in the anti-TNF cohort [odds
ratio 0.5 (95% CI 0.3, 0.8)].
Conclusions. These data add to currently available evidence suggesting that anti-TNF therapy is asso-
ciated with a small but significant overall risk of SI. This must be balanced against the risks associated
with poor disease control or alternative treatments.
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Introduction
RA has detrimental effects on a wide range of health out-
comes, reaching far beyond the damage to the musculo-
skeletal system. RA is associated with increased mortality
and comorbidity from a number of causes compared with
the general population, including infection [1, 2]. Biologic
therapies now bring the opportunity to target precise
pathways within the immune system and inflammatory
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through better disease control and thus a reduction in
the associated comorbidity and mortality. The anti-TNF
drugs were the first biologic agents to become estab-
lished in the management of RA patients who fail to re-
spond to traditional non-biologic DMARDs (nbDMARDs).
However, TNF plays an important role in host defence
[3, 4]. Therefore, the introduction of anti-TNF agents was
accompanied by a need to study and understand the
effect on infection risk of modifying this key pathway.
This article summarizes the latest results from the
British Society for Rheumatology Biologics Register
(BSRBR) on rates of all serious infections (SIs), comparing
nbDMARD with anti-TNF, as well as comparing between
the three anti-TNF agents that were licensed in the UK
between 2001 and 2009 [infliximab (INF), etanercept
(ETN) and adalimumab (ADA)]. As follow-up has accrued,
the BSRBR has acquired sufficient statistical power to be
able to examine time-varying risk, age-specific risks and
differences in outcome of infection.
Methods
The BSRBR is a large national prospective study, estab-
lished to investigate the long-term safety of exposure to
biologic agents in patients with RA. Full details of the
BSRBR methodology have been published previously
[5]. In brief, the study commenced in 2001 alongside na-
tional recommendations that all RA patients prescribed
anti-TNF therapy within the UK should be registered
with the BSRBR. Patients were recruited to the ETN and
INF cohorts from 2001 onwards, while recruitment to the
ADA cohort started in 2003. Recruitment targets of 4000
patients per treated cohort were met for the ETN cohort in
2005, for INF in 2007 and for ADA in 2008. Before recruit-
ment targets were met, we estimated that >80% of
anti-TNF-treated patients with RA in the UK were regis-
tered on the BSRBR. A comparison cohort of biologic-
naı ¨ve patients with active RA [defined as a 28-joint DAS
(DAS-28) >4.2] was recruited in parallel. These patients
had active disease despite current treatment with an
nbDMARD. Patients who were prescribed biologics were
recruited from across the whole of the UK (over 250 hos-
pitals), whereas controls were recruited from just 29 cen-
tres across the UK. The 29 control centres are distributed
across the UK and include a mixture of secondary and
tertiary care rheumatology units in rural and urban settings
in deprived and affluent areas. Ethics approval for this
study was obtained in December 2000 from the
Multicentre Research Ethics Committee (MREC) for the
Northwest of England.
Baseline assessment
Baseline information included demographics, disease
duration, HAQ score, DAS-28 score, steroid use, smoking
history and comorbidity. Steroid use was defined as
actively receiving oral steroids at the time of recruitment.
Follow-up
Information on adverse events was collected in three
ways: 6 monthly questionnaires were sent to the treating
rheumatology team for 3 years and annually thereafter;
questionnaires were sent to the patients every 6 months
(for 3 years); flagging with the UK National Health Service
Information Centre (NHS-IC), which informed the register
of any deaths and the cause of death.
Case definition and verification
Incident cases of SIs were identified from all three sources
of follow-up. SIs were defined as those requiring i.v. anti-
biotics or hospitalization, or those resulting in death. This
analysis was confined to cases that were reported or ver-
ified by the patient’s rheumatologist. Thus, patient-
reported SIs were only included in the analysis if later
verified by a consultant. Events were ascribed to the
anti-TNF agent if they occurred while the patient was
receiving anti-TNF therapy or within 90 days of the first
missed dose. Events were attributed to the most recent
drug in patients who switched anti-TNF therapy. Patients
were censored from this analysis after their first episode
of SI.
Statistical methods
Analysis was restricted to patients with a physician diag-
nosis of RA. All patients had to have at least one returned
consultant follow-up questionnaire before 31 December
2008 (the end of follow-up for this analysis). All patients
were followed from the start of anti-TNF therapy (or regis-
tration for the DMARD cohort) until death, first SI or last
follow-up. Patients within the anti-TNF cohort who
stopped therapy for a reason other than SI contributed
to follow-up time until 90 days after their first missed
dose. If a patient then switched anti-TNF agent, they con-
tributed subsequent follow-up to the new anti-TNF cohort.
Crude incidence rates were calculated as the number
of episodes of SI per 1000 patient-years of follow-up
with 95% CI. To estimate risk differences between the
groups, a survival analysis was performed using a Cox
proportional hazards model. Adjustment was made for
age, gender and calendar year of recruitment. Multi-
variable regression was performed with additional con-
founders identified from an a priori list including smoking,
diabetes, chronic obstructive pulmonary disease (COPD),
steroid use and disease severity (HAQ, DAS-28 and dis-
ease duration as continuous variables). MTX exposure
was adjusted for as a time-varying covariate. Results are
presented for both the whole follow-up period and limited
to pre-specified time windows: 0–6, 6–12, 12–24 and 24–
36 months of treatment. The cohort was then divided into
four groups according to age at registration: <55, 55–64,
65–74 and 575 years. Stratified risk of infection within
each age group was examined as above and the Wald
test was used to look for evidence of a trend.
Finally, outcome following infection was assessed in
two ways: (i) the length of hospital stay was compared
between the two groups using the Mann–Whitney U-test
and (ii) mortality within 30 days following diagnosis of SI
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gression (adjusted for age, gender, comorbidity, smoking,
disease duration and severity, entry year and baseline
steroid use). Missing baseline data were replaced using
multiple imputations. All analyses were done using Stata
10.1 (StataCorp., College Station, TX, USA).
Results
In total, 15396 patients were eligible for inclusion in this
analysis: 11798 in the anti-TNF cohort and 3598 in the
nbDMARD cohort. The baseline characteristics of the pa-
tients are shown in Table 1. In total, 3366 (22%) patients
switched biologic during the follow-up period. Baseline
characteristics relate to the first anti-TNF agent pre-
scribed. The nbDMARD cohort was older and included a
higher proportion of men. Thirty-six per cent of the
nbDMARD cohort and 23% of the anti-TNF cohort were
aged >65 years. Although disease activity was higher in
the anti-TNF cohort, both cohorts had high mean levels of
disease activity. Characteristics were similar across the
three anti-TNF cohorts at baseline. The median duration
of follow-up was 3.9 [interquartile range (IQR) 2.4, 4.9]
years in the anti-TNF cohort and 2.6 (IQR 1.4, 3.8) years
in the nbDMARD cohort.
Within both cohorts, comorbidity (diabetes and COPD)
increases with age up to 75 years (supplementary table 1,
available as supplementary data at Rheumatology Online).
As one might expect, disease duration at study entry
increases with age in both the nbDMARD and anti-TNF
cohorts with the difference between the nbDMARD and
anti-TNF groups being similar in each age band. Mean
disease activity is similar across the age bands for both
the nbDMARD and anti-TNF cohorts. Baseline mean HAQ
score increases with age in the nbDMARD cohort but not
in the anti-TNF cohort. Thus, there is a greater difference
in the baseline mean HAQ score in the nbDMARD
and anti-TNF cohorts in the youngest age band than
in the oldest age band. Baseline steroid exposure rose
dramatically with increasing age in both cohorts, with
18% of the nbDMARD cohort and 40% of the anti-TNF
cohort aged <55 years receiving steroid at baseline,
compared with 36% of the nbDMARD cohort and 55%
of the anti-TNF cohort aged >75 years.
In total, 1808 patients experienced at least one SI
(nbDMARD: 296; anti-TNF: 1512; Table 2). Approximately
one-third of patients who suffered one SI were reported as
having a second SI during the subsequent follow-up. The
proportion did not differ significantly between the two
cohorts (32% DMARD, 28% TNF, P=0.123). All further
analysis considers only the first-reported SI per subject.
The unadjusted rates of SI were higher in the anti-TNF
cohort (42 vs 32 events per 1000 patient-years of
follow-up). Univariate analysis of the a priori list of poten-
tial confounders identified age, male gender, DAS-28, dis-
ease duration, diabetes, COPD, baseline steroids and
smoking all as significant predictors of infection (supple-
mentary table 2, available as supplementary data at
Rheumatology Online). The adjusted rate of SI was 20%
higher in the anti-TNF cohort than in the nbDMARD cohort
[adjusted hazard ratio (adjHR) 1.2 (95% CI 1.1, 1.5)]. The
highest crude SI rate was seen with INF [46/1000 (95% CI
42, 50)], followed by ADA [43/1000 (95% CI 39, 47)] and
ETN [38/1000 (95% CI 35, 42)]. However, in the adjusted
analysis, there was no significant difference in SI rates
between the three anti-TNF agents. The analysis was
also performed excluding patients who switched biologic
(censoring them at the time of first switch): adjHR 1.2
(95% CI 1.0, 1.4).
Time-varying risk
The adjHR of SI in the anti-TNF vs the DMARD cohort was
the highest in the first 6 months of therapy [adjHR in all
anti-TNF cohort 1.8 (95% CI 1.3, 2.6)]. The risk then
decreased over time with the lowest risk observed be-
tween 24 and 36 months [adjHR in all anti-TNF cohort
0.9 (95% CI 0.6, 1.3)]. A similar pattern was observed
when analysis was stratified by anti-TNF therapy.
TABLE 1 Baseline characteristics of DMARD and anti-TNF cohorts
Characteristic
DMARD
(n=3598)
All TNF
(n=11798) P-value
ETN
(n=4129)
INF
(n=3467)
ADA
(n=4202)
Age, mean (S.D.), years 60 (12) 56 (12) <0.001 56 (12) 56 (12) 57 (12)
Age, n (%), years
<55 1146 (32) 5206 (44) <0.001 1841 (45) 1552 (45) 1813 (43)
55–64 1162 (32) 3825 (32) <0.001 1348 (33) 1120 (32) 1357 (32)
65–74 926 (26) 2280 (19) <0.001 777 (19) 635 (18) 868 (21)
575 364 (10) 487 (4) <0.001 163 (4) 160 (5) 164 (4)
Gender, female (%) 2982 (72) 8777 (76) <0.001 3182 (77) 2620 (76) 3149 (76)
Current smoker, n (%) 847 (24) 2566 (22) 0.002 843 (21) 757 (22) 966 (23)
Ex-smoker, n (%) 1425 (40) 4486 (38) 0.002 1574 (38) 1310 (38) 1602 (38)
Never smoker, n (%) 1308 (37) 4670 (40) 0.002 1686 (41) 1382 (40) 1602 (38)
Diabetes, n (%) 234 (6.7) 675 (5.8) 0.045 254 (6.2) 169 (4.9) 252 (6.1)
COPD, n (%) 300 (8) 565 (5) <0.001 222 (5) 165 (5) 178 (4)
Disease duration, median (IQR), years 6 (1–15) 11 (6–19) <0.001 12 (6–19) 12 (6–19) 10 (5–18)
Baseline steroid use, n (%) 778 (23) 5127 (44) <0.001 1972 (48) 1607 (46) 1613 (39)
DAS-28, mean (S.D.) 5.1 (1.3) 6.6 (1.0) <0.001 6.6 (1.0) 6.6 (1.0) 6.5 (1.0)
HAQ score, mean (S.D.) 1.5 (0.8) 2.0 (0.6) <0.001 2.1 (0.6) 2.1 (0.5) 1.9 (0.6)
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The crude rate of infection increased markedly with
increasing age in both cohorts (Table 3). However, the
adjHR was similar across the age bands (Table 3), with
no significant trend (P=0.210). An alternative analysis
dividing the cohort into those aged under or over
65 years found similar adjHR in both age groups over
the entire period of follow-up [adjHR 1.3 (95% CI 1.1,
1.6) for those <65 years and adjHR 1.1 (95% CI 0.8, 1.4)
for those >65 years] as well as in an analysis limited to the
first 6 months of therapy [adjHR 1.9 (95% CI 1.1, 3.0) for
those <65 years and adjHR 1.6 (95% CI 0.9, 2.8) for those
>65 years].
Outcome
The duration of hospital stay did not differ between
anti-TNF [median stay 6 days (IQR 3–12)] and nbDMARD
[median stay 7 days (IQR 3–14)] treated patients (Table 4).
However, there was a much lower 30-day mortality rate
among patients in the anti-TNF cohort [anti-TNF 7%;
DMARD 16%; P<0.001; adjusted odds ratio 0.5 (95% CI
0.3, 0.8)].
Discussion
RA patients have been recognized to be at increased risk
of infection for several decades [6]. Some of the increased
risks is attributable to the disease process itself and some
to the immunosuppressive properties of its treatment, in
particular CSs. TNF plays an important role in the control
of infection. In particular, TNF release from macrophages
appears crucial in the maintenance and formation of gran-
ulomata, as well as playing a critical role in the defence
against invasion by intracellular organisms. TNF also has
roles in leucocyte trafficking and IC clearance [7]. TNF
inhibition is a risk factor for a variety of infections in
animal models [8, 9]. However, anti-TNF therapies may
also have potential beneficial effects on the immune
system in disease states such as RA by reducing the
immune abnormalities intrinsic to the disease.
Several approaches have been used to try and quantify
the risks of infection associated with anti-TNF therapy in
RA. Meta-analyses of randomized controlled trials (RCTs)
have produced conflicting results [10, 11]. However, al-
though the RCT is the gold standard for evaluating drug
efficacy, RCTs often lack power (in terms of both numbers
and duration of follow-up) to evaluate specific adverse
events. In addition, patients enrolled in RCTs are a very
select group of patients who do not wholly reflect the RA
cohorts seen in routine clinical practice [12]. These short-
comings can be addressed by large-scale prospective
observational studies, although these lack the advantages
of randomization and so are subject to confounding by
indication.
The observational design of the BSRBR means patients
are not randomized to their respective treatment, and
therefore there may be differences in clinical characteris-
tics. This needs to be considered when comparing rates
of SI between the two cohorts as any observed difference
may reflect the characteristics of the patients selected for
treatment rather than an effect of the treatment itself. The
detailed collection of baseline data within the BSRBR
allows for adjustment of these patient characteristics
that may potentially confound any association between
anti-TNF and SI. However, despite this there remains
the possibility of residual unmeasured confounding.
CS exposure deserves particular attention in this ana-
lysis. Although adjustment has been made for baseline CS
exposure, it has not been possible to adjust for CSs as a
time-varying covariate. This is because the BSRBR does
not have information on whether patients were receiving
steroids immediately before any infection. Patients who
commence and respond to anti-TNF are likely to require
less steroids during their follow-up period (and the con-
verse may be true with the nbDMARD cohort). If this is the
case, our adjusted model may be underestimating the
effect of anti-TNF.
The BSRBR has previously reported a 20% non-
significant increase in the rate of SI between TNF-treated
individuals and controls [13]. In addition, we have re-
ported that intracellular bacterial species (e.g. Listeria,
Salmonella) occurred more frequently in the anti-TNF
cohort and specifically Mycobacterium tuberculosis infec-
tions were substantially increased [13, 14]. Despite longer
TABLE 2 Overall and time-dependent risk of SI
Results nbDMARD All TNF ETN INF ADA
Follow–up, pyrs 9259 36230 15874 9622 10733
Number of SIs 296 1512 609 441 462
Rate/1000 pyrs (95% CI) 32 (28, 36) 42 (40, 44) 38 (35, 42) 46 (42, 50) 43 (39, 47)
Unadjusted HR Ref. 1.5 (1.3, 1.7) 1.4 (1.2, 1.6) 1.6 (1.4, 1.9) 1.4 (1.2, 1.7)
adjHR
a (95% CI) Ref. 1.2 (1.1, 1.5) 1.2 (1.0, 1.4) 1.3 (1.1, 1.6) 1.3 (1.1, 1.5)
Follow-up, months
0–6 Ref. 1.8 (1.2, 2.6) 1.8 (1.2, 2.7) 1.7 (1.1, 2.6) 1.8 (1.2, 2.7)
6–12 Ref. 1.4 (0.9, 2.0) 1.3 (0.8, 2.0) 1.4 (0.9, 2.2) 1.4 (0.9, 2.1)
12–24 Ref. 1.2 (0.8, 1.6) 1.1 (0.8, 1.5) 1.1 (0.7, 1.5) 1.3 (0.9, 1.8)
24–36 Ref. 0.9 (0.6, 1.3) 0.8 (0.6, 1.2) 1.2 (0.8, 1.8) 0.8 (0.6, 1.3)
aAdjusted for age, gender, COPD, diabetes, smoking, disease duration, DAS, HAQ, entry year, steroid use and MTX use.
pyrs: patient-years.
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increase in risk, which is now statistically significant. A
small but significant increase in the risk of SI has also
been reported by the German and Swedish Biologics
Registries [15, 16].
However, presenting a single estimate for the risk of SI
is misleading as the risk is not constant over time. In the
first 6 months of therapy, the risk of SI was 80% higher in
the anti-TNF-treated cohort than in the non-biologic-
treated controls. Askling and Dixon [17] reviewed all pub-
lished papers on infection risk associated with anti-TNF
therapy in RA and found that the risk was highest in the
first few months and then declined. This variation in risk is
probably explained by a combination of factors. First,
there will be a number of patients who are at higher base-
line risk. When these individuals develop an SI, they will
stop their drug and no longer contribute to the anti-TNF
cohort. This results in a depletion of susceptible individ-
uals (a healthy user effect), and so reduces the apparent
risk of the drug. In addition to this, there may be a true
time-dependent change in the drug safety profile. A per-
sistent blockade of one cytokine pathway may lead to
up-regulation of other immune-signalling pathways that
can compensate for the lack of TNF. Also as patients
become established on anti-TNF therapy, their RA be-
comes better controlled, their dose of steroids can be
reduced, they become more mobile and disease-driven
alterations in natural immunity reduce. This may in part
explain why one meta-analysis of RCT data showed an
increased risk [11], given that RCTs predominantly focus
on the early period of exposure.
We also considered the question of differential risk
between the three anti-TNF agents. The German registry
reported a lower risk of Herpes varicella zoster skin
infections in patients treated with ETN than in those trea-
ted with the mAb therapies (INF and ADA). We reported a
similar pattern with M. tuberculosis infections [18, 19].
However, we found no significant difference in risk be-
tween the three agents for overall SIs, either in the first
6 months or overall.
We next examined the risk across different age groups.
Managing RA in older patients is challenging, as it is
complicated by both comorbidity and polypharmacy.
Traditionally, clinical practice has been to assume a
higher risk with nbDMARDs in the elderly and to prefer
to use low doses of oral steroids [20]. This pattern was
seen in the BSRBR data set, with higher baseline steroid
exposure among those patients aged 575 years.
Steroids, even in low doses, are an important risk factor
for SI [21–25]. Despite the high background risk of infec-
tion in the elderly patient with RA, our data do not support
the notion that anti-TNF therapy increases this risk any
further in the elderly patient than in the younger patient.
This finding is consistent with post hoc analyses from clin-
ical trials of ETN vs placebo, which have compared rates
of infection in those under or over 65 years of age [26, 27].
Several observational studies have also addressed this
issue. Schneeweiss et al. [28] did not find an increased
risk of infection in anti-TNF users compared with those
receiving MTX among US Medicare beneficiaries.
Genevay et al. [29] also reported no differences in rates
of discontinuation or SI in a Swiss cohort of 1571 RA
patients divided into younger (<65 years) or older
(>65 years) age groups. Our results add to this literature
by presenting data stratified into even older age groups.
However, it is important to note that although the relative
risk of infection was similar in all age groups, given the
higher background risk in those patients aged >65 years,
TABLE 3 Risk of SI according to age
DMARD Anti-TNF
Age
band, years
Follow-up,
pyrs
Infections
(n)
Events/1000 pyrs
(95% CI)
Follow-up,
pyrs
Infections
(n)
Events/1000 pyrs
(95% CI)
AdjHR
a,b
(95% CI)
<55 2951 52 18 (13, 23) 17100 477 28 (25, 31) 1.2 (0.8, 1.6)
55–64 2964 76 26 (20, 32) 11608 533 46 (42, 50) 1.4 (1.1, 1.9)
65–74 2414 125 52 (43, 62) 6325 395 62 (56, 69) 0.9 (0.7, 1.2)
>75 931 43 46 (33, 62) 1198 99 83 (67, 101) 1.5 (0.9, 2.6)
aAdjusted for age, gender, COPD, diabetes, smoking, disease duration, DAS, HAQ, entry year, steroid use and MTX use.
bWald test for significance between groups confirms non-significance (P=0.210). pyrs: patient-years.
TABLE 4 Comparison of outcome of SIs
Outcome DMARD Anti-TNF P-value Odds ratio
a (95% CI)
Median hospital stay in days (IQR) 7 (3, 14) 6 (3, 12) 0.1318 Not applicable
Deaths within 30 days of infection, n (%) 47 (16) 110 (7) <0.001 0.5 (0.3, 0.8)
aAdjusted for age, gender, COPD, diabetes, smoking, disease duration, DAS, HAQ, entry year, steroid use and MTX use.
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age group. To put this into context, during the first 6
months of treatment, in those aged <65 years, 25 (95%
CI 20, 31) RA patients would need to be treated to ob-
serve one additional SI, while in those aged >65 years the
equivalent number is 19 (95% CI 16, 23).
It is possible that physicians may have a lower threshold
for hospital admission for an RA patient with infection if the
patient is receiving anti-TNF than if they are not. Thus, al-
though the patients in the anti-TNF cohort had more infec-
tions that satisfied the definition of SI, these infections may
not, in fact, have been more severe. To explore this further,
we compared the length of hospital stay and 30-day
mortality risk between our two cohorts. The similar length
of hospital stay suggests that the infections in anti-
TNF-treated patients were not more severe than those in
nbDMARD-treated patients. The 50% lower 30-day mor-
tality rate in the anti-TNF cohort is intriguing. In animal
models of sepsis, treatment with anti-TNF therapy before
the onset of sepsis was found to be beneficial, presumably
by suppressing the inflammatory response [30]. Human
trials did not show any significant advantage of adding
TNF inhibitors to a sepsis regimen [31, 32], although the
human trials could not initiate anti-TNF therapy until after
sepsis was established. In the context of the BSRBR, pa-
tients had effectively been pre-treated with anti-TNF ther-
apy before developing any infection. It is important to
stress that the design of this study precludes any definite
proof of causality in this association. However, the size and
strength of this association would certainly support the
need for additional research in this area.
Conclusions
These data add to the currently available evidence sug-
gesting that anti-TNF therapy is associated with a small
but significant overall risk of SI. The risk is highest in the
first 6 months of therapy and then falls. This should be
explained to the individual patient. Increasing age is an
important risk factor for infection in patients with RA.
Some of this increased risk may be related to steroid
usage. To date, there is no convincing evidence that the
relative risk of infection with anti-TNF therapy also in-
creases with age. Further research is needed to help clin-
icians balance the risk of treatment options in elderly
subjects. Finally, there is a significantly lower 30-day mor-
tality rate following SI in RA patients treated with anti-TNF
agents.
Rheumatology key messages
. Anti-TNF therapy is associated with SIs.
. This risk is greatest early on during treatment.
. The HR for infection is similar across all ages.
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Appendix 1
BSRBR Control Centre Consortium
The BSRBR Control Centre Consortium consists of the
following institutions (all in the UK): Antrim Area Hospital,
Antrim (Dr Nicola Maiden), Cannock Chase Hospital,
Cannock Chase (Dr Tom Price), Christchurch
Hospital, Christchurch (Dr Neil Hopkinson), Derbyshire
Royal Infirmary, Derby (Dr Sheila O’Reilly), Dewsbury and
District Hospital, Dewsbury (Dr Lesley Hordon), Freeman
Hospital,Newcastle-upon-Tyne(DrIanGriffiths),Gartnavel
General Hospital, Glasgow (Dr Duncan Porter), Glasgow
Royal Infirmary, Glasgow (Prof Hilary Capell), Haywood
Hospital, Stoke-on-Trent (Dr Andy Hassell), Hope
Hospital, Salford (Dr Romela Benitha), King’s College
Hospital, London (Dr Ernest Choy), Kings Mill Centre,
Sutton-in-Ashfield (Dr David Walsh), Leeds General
Infirmary, Leeds (Prof Paul Emery), Macclesfield District
General Hospital, Macclesfield (Dr Susan Knight),
Manchester Royal Infirmary, Manchester (Dr Ian Bruce),
Musgrave Park Hospital, Belfast (Dr Allister Taggart),
Norfolk and Norwich University Hospital, Norwich
(Prof David Scott), Poole General Hospital, Poole (Dr Paul
Thompson), Queen Alexandra Hospital, Portsmouth
(Dr Fiona McCrae), Royal Glamorgan Hospital,
Glamorgan (Dr Rhian Goodfellow), Russells Hall Hospital,
Dudley (Prof George Kitas), Selly Oak Hospital, Selly Oak
(Dr Ronald Jubb), St Helens Hospital, St Helens (Dr Rikki
Abernethy), Weston General Hospital, Weston-super-Mare
(Dr Shane Clarke/Dr Sandra Green), Withington Hospital,
Manchester (Dr Paul Sanders), Withybush General
Hospital, Haverfordwest (Dr Amanda Coulson), North
Manchester General Hospital (Dr Bev Harrison), Royal
Lancaster Infirmary (Dr Marwan Bukhari) and the Royal
Oldham Hospital (Dr Peter Klimiuk).
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